Antibody Information

General Information of This Antibody
Antibody ID
ANI0SEONV
Antibody Name
Ozuriftamab
Organization
BioAtla, LLC
Indication
Solid tumors
Synonyms
BA302; BA-302; BA 302
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Chimeric IgG1-kappa
Antigen Name
Tyrosine-protein kinase transmembrane receptor ROR2 (ROR2)
  Antigen Info 
ChEMBI ID
CHEMBL5095432
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
EVQLVQSGAEVKKPGESLRISCKGSGYTFTEYTMHWVRQAPGQGLEWMGGINTNNGGTGY
NQKFKGRVTISADKSISTAYLQWSSLKASDTAMYYCAHGSLYSYGNSYFDYWGQGTLVTV
SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
    Click to Show/Hide
Heavy Chain Varible Domain
EVQLVQSGAEVKKPGESLRISCKGSGYTFTEYTMHWVRQAPGQGLEWMGGINTNNGGTGY
NQKFKGRVTISADKSISTAYLQWSSLKASDTAMYYCAHGSLYSYGNSYFDYWGQGTLVTV
SS
    Click to Show/Hide
Heavy Chain Constant Domain 1
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
    Click to Show/Hide
Heavy Chain Constant Domain 2
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
    Click to Show/Hide
Heavy Chain Constant Domain 3
GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
    Click to Show/Hide
Heavy Chain Hinge Region
EPKSCDKTHTCPPCP
    Click to Show/Hide
Heavy Chain CDR 1
GYTFTEYT
    Click to Show/Hide
Heavy Chain CDR 2
INTNNGGT
    Click to Show/Hide
Heavy Chain CDR 3
AHGSLYSYGNSYFDY
    Click to Show/Hide
Light Chain Sequence
AIQLTQSPSSLSASVGDRVTITCSATSSVSYMHWYLQKPGQSPQLLIYGTSNLASGVPDR
FSGSGSGTDFTLKISRVEAEDVGVYYCQQRSSYPFTFGQGTKVEIKRTVAAPSVFIFPPS
DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL
SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain Varible Domain
AIQLTQSPSSLSASVGDRVTITCSATSSVSYMHWYLQKPGQSPQLLIYGTSNLASGVPDR
FSGSGSGTDFTLKISRVEAEDVGVYYCQQRSSYPFTFGQGTKVEIK
    Click to Show/Hide
Light Chain Constant Domain
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain CDR 1
SSVSY
    Click to Show/Hide
Light Chain CDR 2
GTS
    Click to Show/Hide
Light Chain CDR 3
QQRSSYPFT
    Click to Show/Hide
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Ozuriftamab vedotin [Phase 2]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Objective Response Rate (ORR)
32%
Patients Enrolled
Eligibility covers stage III-IV SCCHN (oropharynx/larynx, excluding nasopharynx) in neoadjuvant/recurrent/metastatic settings; requires ECOG 0-1, measurable disease, and adequate organ function. Exclusions: prior PD-1/L1/CTLA-4 therapy (unless second-line), Grade≥3 mAb allergies, active HIV/HBV/HCV, or pregnancy.
Related Clinical Trial
NCT Number NCT05271604  Clinical Status PHASE2
Clinical Description
A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Primary Endpoint
The efficacy endpoint includes confirmed ORR per RECIST v1.1 over 24 months, alongside AE/SAE incidence graded by CTCAE v5.
Other Endpoint
Additional efficacy measures assess DOR, PFS, BOR, DCR (CR/PR/SD≥12w), TTR, OS, and CR rate-all evaluated for up to 24 months.
Experiment 2 Reporting the Activity Date of This ADC [2]
Patients Enrolled
Eligible patients have advanced/metastatic solid tumors (NSCLC/TNBC/STS preferred) refractory to SOC, measurable disease, ECOG 0-1, and adequate organ function; exclusions include active CNS metastases, prior auristatin therapy, Grade≥3 mAb allergies, HIV/HBV/HCV, or pregnancy within 4 weeks of surgery.
Related Clinical Trial
NCT Number NCT03504488  Clinical Status PHASE1|||PHASE2
Clinical Description
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
Primary Endpoint
Phase 1 assesses DLTs, MTD, and AE/SAE frequency/severity over 24 months; Phase 2 evaluates confirmed ORR (CR/PR rate).
Other Endpoint
Phase 1 tracks PK profiles (ADC/MMAE plasma levels, Cmax, AUC), immunogenicity (ADA development), and efficacy (ORR, DOR, PFS, BOR, DCR, TTR, OS, tumor size change) across 24 months; Phase 2 expands efficacy endpoints.
Experiment 3 Reporting the Activity Date of This ADC [3]
Patients Enrolled
Eligible participants are women aged ≥18 with platinum-resistant high-grade serous ovarian, fallopian tube, or peritoneal cancer, confirmed histologically, with measurable disease per RECIST 1.1, amenable to biopsies, and adequate organ function. Exclusion criteria include uncontrolled comorbidities, prior malignancies affecting safety assessment, active infections, severe autoimmune disorders, CNS metastases requiring steroids, pregnancy, and recent live vaccines.

   Click to Show/Hide
Related Clinical Trial
NCT Number NCT04918186  Clinical Status PHASE2
Clinical Description
An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Primary Endpoint
The primary objective is to assess the objective response rate (ORR) by investigator evaluation using RECIST 1.1 criteria over 36 months, aiming to identify effective immunotherapy combinations for high-grade serous ovarian cancer for future randomized trials.
Other Endpoint
Key secondary endpoints include evaluating ORR via RECIST 1.1, progression-free survival (PFS) and overall survival (OS) by RECIST 1.1 and iRECIST, as well as monitoring adverse event frequency and severity over 36 months.
References
Ref 1 A Phase 2 Open Label Study of BA3021 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Ref 2 CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
Ref 3 Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer